Results 231 to 240 of about 28,538 (266)
Some of the next articles are maybe not open access.
Treatment of cutaneous lupus erythematosus
Lupus, 2010In patients with cutaneous lupus erythematosus (CLE) and mild skin involvement, local therapy consisting of topically applied pharmacological agents, e.g., topical/intralesional steroids, may be sufficient. Recent reports have also shown efficacy of topical calcineurin inhibitors in patients with CLE, particularly on the face.
A, Kuhn, F, Ochsendorf, G, Bonsmann
openaire +2 more sources
Bullous subacute cutaneous lupus erythematosus
Clinical and Experimental Dermatology, 2004We describe a 59-year-old woman, with a history of autoimmune disease and disseminated uterine leiomyosarcoma, who developed a photoaggravated, blistering skin eruption. An initial rash, at the outset of treatment with chemo- and radiotherapy, resembled erythema multiforme.
Perera, G K, Black, M M, McGibbon, D H
openaire +3 more sources
Thalidomide in Cutaneous Lupus Erythematosus
American Journal of Clinical Dermatology, 2003For nearly 50 years, thalidomide has struggled between success and controversy. After causing an epidemic of phocomelia and other birth defects during the 1960s, affecting thousands of neonates, thalidomide was used as a sedative in selective disorders including leprosy.
Michelle T, Pelle, Victoria P, Werth
openaire +2 more sources
Poikilodermatous Subacute Cutaneous Lupus erythematosus
Dermatology, 2003<i>Background:</i> Subacute cutaneous lupus erythematosus (SCLE) is a distinct subset of lupus erythematosus with unique clinical, immunological and genetic features. Among the unusual variants of SCLE, there is a poikilodermic presentation. However, to date, only 1 case of poikilodermatous SCLE has been reported.
Angelo V, Marzano +2 more
openaire +2 more sources
Pathogenesis of cutaneous lupus erythematosus
Clinics in Dermatology, 1985Antibody-dependent mechanisms of tissue damage are the principle mechanism of disease in systemic and cutaneous lupus erythematosus. Antibody-dependent mechanisms of keratinocyte damage appear to be a primary pathogenetic factor in all forms of papulosquamous cutaneous lupus. Photosensitive papulosquamous lupus syndromes, such as subacute cutaneous LE,
D A, Norris, L A, Lee
openaire +2 more sources
Histopathology of cutaneous lupus erythematosus
Clinics in Dermatology, 1985The basic histopathologic feature of all cutaneous lesions of lupus erythematosus involves a perivascular mononuclear cell infiltrate with subsequent involvement of the epidermis and appendages. The various histologic alterations affecting the epidermis, dermis, and adnexal structures reflect the particular type of lesion biopsied and the duration of ...
A F, Hood, E R, Farmer
openaire +2 more sources
Cutaneous lupus erythematosus: a review
Dermatologic Clinics, 2002This article will review and update information about the pathogenesis, clinical presentation, diagnosis, and treatment of cutaneous lupus erythematosus. Lupus erythematosus (LE) can present as a skin eruption, with or without systemic disease. Cutaneous LE is subdivided into chronic cutaneous LE, subacute cutaneous LE and acute LE.
Purvisha, Patel, Victoria, Werth
openaire +2 more sources
Management of cutaneous lupus erythematosus
Clinics in Dermatology, 1985Abstract Therapy of cutaneous lupus erythematosus is both an art and a science. The interplay of cosmetic and systemic factors must be understood and managed by the physician, who must, following recognition and diagnosis of the problem, discuss prognosis and life-style modification with the patient. Extensive reassurance usually is necessary.
openaire +2 more sources
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
Nature Medicine, 2022Andreas Mackensen, Sebastian Boeltz
exaly